Eli Lilly and Company $LLY Stock Holdings Cut by Partnership Wealth Management LLC

Partnership Wealth Management LLC lowered its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 2.4% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 21,236 shares of the company’s stock after selling 528 shares during the quarter. Eli Lilly and Company makes up approximately 12.5% of Partnership Wealth Management LLC’s holdings, making the stock its biggest position. Partnership Wealth Management LLC’s holdings in Eli Lilly and Company were worth $16,203,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Wealth Preservation Advisors LLC purchased a new stake in Eli Lilly and Company during the first quarter valued at approximately $27,000. Sumitomo Mitsui Financial Group Inc. bought a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at $27,000. Evolution Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company in the 2nd quarter worth $29,000. Steph & Co. raised its holdings in Eli Lilly and Company by 290.0% in the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after purchasing an additional 29 shares during the period. Finally, Financial Gravity Companies Inc. bought a new position in Eli Lilly and Company in the 2nd quarter worth $31,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on LLY shares. Wolfe Research upped their price target on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 3rd. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. Guggenheim reiterated a “buy” rating and issued a $1,163.00 price target on shares of Eli Lilly and Company in a research report on Wednesday, December 3rd. Berenberg Bank increased their price objective on shares of Eli Lilly and Company from $830.00 to $950.00 and gave the stock a “hold” rating in a research note on Tuesday, December 2nd. Finally, Truist Financial lifted their target price on shares of Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the company a “buy” rating in a research note on Wednesday, November 19th. Four analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $1,141.73.

Eli Lilly and Company Price Performance

LLY stock opened at $1,056.57 on Friday. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. The company’s fifty day moving average price is $956.00 and its 200-day moving average price is $828.10. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,111.99. The company has a market capitalization of $998.86 billion, a PE ratio of 51.69, a price-to-earnings-growth ratio of 1.31 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The company had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same period in the previous year, the firm posted $1.18 EPS. Eli Lilly and Company’s revenue for the quarter was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, February 13th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.